Current pharmaceutical design最新文献

{"title":"From Discovery to the Future Medical Applications of Venom-derived Analgesic Peptides for the Treatment of Peripheral Pains.","authors":"Sedigheh Bagheri-Ziari, Kamran Pooshang Bagheri","doi":"10.2174/0113816128368659250805054737","DOIUrl":"https://doi.org/10.2174/0113816128368659250805054737","url":null,"abstract":"<p><p>Despite the availability of current peripheral pain medications, patients continue to experience acute pain and often need more potent analgesic options. As a result, the discovery of novel molecules is of significant importance. In recent years, the functional properties of peptides have opened new possibilities for pain treatment. This review explores the peptides derived from venoms that target peripheral pain pathways, while briefly investigating the peptides involved in the pathophysiology of peripheral pain. Key peripheral pain receptors include transient receptor potential vanilloid 1 and 2 (TRPV1 and TRPV2), voltage-gated calcium (Ca++), sodium (Na+), and potassium (K+) channels, as well as acid-sensing ion channels (ASICs). Venoms have shown remarkable potential as a source of new therapeutic molecules. Among venomous creatures, cone snails, snakes, sea anemones, tarantulas, scorpions, and spiders are known to possess analgesic peptides. These peptides exert their pain-relieving effects by influencing ion channels and other receptors. Recent studies have investigated the mechanisms of peptides isolated from venoms in various types of pain. These peptides exhibit robust analgesic effects in animal models. This study demonstrates that analgesic peptides derived from venom effectively reduce peripheral pain intensity, presenting promising new molecules for potential medical applications in peripheral pain management.</p>","PeriodicalId":10845,"journal":{"name":"Current pharmaceutical design","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144946074","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ibrutinib Loaded Nanostructured Lipid Carriers for the Management of Chronic Lymphocytic Leukemia: Synchronizing In Silico, In Vitro, and In Vivo Studies.","authors":"Anjali Patel, Aneri Desai, Bhavin Vyas, Pintu Prajapati, Pranav Shah","doi":"10.2174/0113816128378420250804145740","DOIUrl":"https://doi.org/10.2174/0113816128378420250804145740","url":null,"abstract":"<p><strong>Introduction: </strong>Ibrutinib is a selective tyrosine kinase inhibitor used to treat chronic lymphocytic leukemia (CLL). However, it has low oral bioavailability (2.9%), which is attributed to low solubility (0.002 mg/mL) and a first-pass effect. Ibrutinib-loaded nanostructured lipid carriers (IBR-NLCs) were prepared and investigated in this study to overcome the solubility and presystemic metabolism issues. The goal of the current study was to formulate IBR-NLCs for enhanced bioavailability. IBR-NLCs were optimized using a 32 factorial design and evaluated using various in vitro and in vivo parameters.</p><p><strong>Methods: </strong>IBR interaction with solid lipid (Glyceryl monostearate) and liquid lipid (oleic acid) was studied using molecular docking. The hot-melt ultrasonication method was used to formulate IBR-NLCs, and a 32 factorial design was used for optimization. Particle size, PDI, zeta potential, entrapment efficiency, DSC, XRD, FTIR, SEM, and in vitro study were used to evaluate the NLCs. HepG2 cell lines were used to study the in vitro cytotoxicity of IBR-NLCs and IBR suspension. IBR-NLCs were administered to male Wistar rats in the presence and absence of cycloheximide (CXI) to compare pharmacokinetic parameters.</p><p><strong>Results: </strong>Molecular docking confirmed good interaction between IBR-GMS and IBR-oleic acid. The optimized IBR-NLCs showed particle size, PDI, zeta potential, and %EE of 154.5 ± 0.7 nm, 0.2 ± 0.0, -25.8 ± 1.1 mV, and 84.0 ± 1.2%, respectively. The IC50 values of IBR suspension and IBR-NLCs were 3.03 and 4.155 μg/mL. The AUC0-24 of IBR-NLCs administered in the absence of CXI was 1.60 times higher than the AUC0-24 values in the presence of CXI, indicating lymphatic transport.</p><p><strong>Conclusion: </strong>IBR-NLCs appear to be promising as a novel innovative nanocarrier for the management of CLL.</p>","PeriodicalId":10845,"journal":{"name":"Current pharmaceutical design","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144946048","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Innovations in mRNA-Based Nanoparticle for the Treatment of Ocular Disorders: A Comprehensive Review.","authors":"Krishana Kumar Sharma, Sumit Durgapal, Siddhant Jai Tyagi, Prakhar Varshney, Gajendra Kumar","doi":"10.2174/0113816128391408250804231522","DOIUrl":"https://doi.org/10.2174/0113816128391408250804231522","url":null,"abstract":"<p><p>The eye, due to its complex anatomy and physiology, presents numerous barriers that restrict the access of drug molecules to the site of action for the maintenance of optimal concentration. Thus, limited drug bioavailability is one of the significant issues with commercially existing drug delivery systems in achieving overall therapeutic effectiveness. Recently, the field of ocular health and management has garnered much attention for the innovation of efficient nanotechnology approaches to overcome the constraints imposed by the intricate anatomy and physiology of the eye. Hypothesizing that the conjugation of mRNA-based therapies with the latest nano delivery systems can overcome these barriers, this review was designed to explore the outstanding potential of these approaches for the management of ocular disorders. With extensive investigations of current findings, the authors believe that such integrations present exciting opportunities to pave the way for the development of effective approaches for various ocular disorders such as uveitis, Leber congenital amaurosis, age-related macular degeneration, retinitis pigmentosa, and many more. Moreover, the approaches exploiting the combination of mRNA and nanotechnology offer effective solutions to address the limitations of currently available management strategies. This review presents various innovative mRNA-based nanotechnology approaches, their mechanisms, challenges, and prospects for further development, focusing on the immense potential of mRNA-based strategies to revolutionize the landscape of ocular therapeutics.</p>","PeriodicalId":10845,"journal":{"name":"Current pharmaceutical design","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144946030","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nutraceutical Rumex nervosus as a Natural Drug Candidate; its Metabolite Profiling and Pharmacological Estimation for Health Applications.","authors":"Sidra Islam, Arusa Aftab, Zainab Maqbool, Zubaida Yousaf, Zill-E-Huma Aftab","doi":"10.2174/0113816128360594250725110421","DOIUrl":"https://doi.org/10.2174/0113816128360594250725110421","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;Rumex nervosus Vahl is a phenomenal plant from Arabian Peninsula and East African areas. It potentially contains massive therapeutic phytochemicals, including Omeprazole, sitosterols, fatty acids, flavonoids and carotenes. Omepazole (a commercial drug) is used to treat stomach ulcers, gastroesophageal reflux and cardiac disorders. Beta-sitosterol (commercial drug) reduces cholesterol levels and body swelling. It is also known to manage rheumatoid arthritis.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methodology: &lt;/strong&gt;The present study evaluated the pharmacological potential and metabolite profiling of Rumex nervosus through various extracts. The extraction was performed using different solvents (Petroleum ether, Chloroform, n-Hexane, Butanol, Methanol, and distilled water) through soxhlet extraction method. Serial dilutions of (100-3.125 mg/mL) were prepared. The biological activities, antimicrobial, anti-diabetic, Hemolytic, anti-inflammatory, and antioxidant (DPPH radical Scavenging, Total anti-oxidant and total phenolic content assays) were performed. Statistical analysis of experimental data was carried out by using SPSS Version 20 and Origin 6.0. Data was represented as mean ± standard deviation (n=3). Differences among mean values were determined using Two-way ANOVA and Tukey's test. The level of statistical significance was set at p ≤ 0.05. The potential extracts were further analyzed for phytochemicals through GC-MS and Network pharmacology (In silico approach).&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;The plant exhibited the best antioxidant activity (86.7% ± 1.92) at 100 mg/mL with distilled water extract. The highest anti-inflammatory activity (90.64 ± 2.34) (88.31 ± 2.37) was given by n-butanol and distilled water extracts at 100 mg/mL. The optimum anti-diabetic activity (92.78 ± 1.89) was observed at 100 mg/mL with n-butanol.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Discussion: &lt;/strong&gt;The maximum zone of inhibition was measured with n-butanol extract against Pseudomonas aeruginosa (36.67 ± 0.32) at 100mg/mL, and in the case of Xanthomonas oryzae again n-butanol extract showed maximum zone of inhibition (30.47 ± 0.32) at 100 mg/mL. The maximum fungal zone of inhibition (22.33 ± 0.40) was noticed with n-butanol extract against Fusarium oxysporom at 100 mg/mL, and in the case of Aspergillus niger maximum fungal zone of inhibition was measured with n-butanol extract (16.20 ± 0.25) at 100 mg/mL. Hemolysis activity was highest (4.12 ± 0.01) with the methanol extract at 3.125 mg/mL. R. nervosus displayed the best activities with n-butanol and distilled water extract. GCMS and network pharmacology combined approach identified seven phytochemicals associated with oxidative stress and infectious diseases (1-Tetradecanol, Stigmast-5-ene, Phthalic acid 2-ethylhexyl isohexyl ester, A-Norcholestan-3-one, 5-ethenyl-, (5.beta.), 16-Heptadecenal, gamma-Sitosterol, Omeprazole). Degree score method selected 10 top hub genes, including AKT1, TNF, and EGFR, as potential targets fo","PeriodicalId":10845,"journal":{"name":"Current pharmaceutical design","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144945797","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Organic Fluorophores Conjugated with Pyridinium Acceptor: A Review on Design, Synthesis, and Application in Mitochondrial Imaging.","authors":"Pradip Debnath","doi":"10.2174/0113816128395084250708080830","DOIUrl":"https://doi.org/10.2174/0113816128395084250708080830","url":null,"abstract":"<p><p>Mitochondria are known as the powerhouse of eukaryotic cells. They play a crucial role in several biological processes and maintain cellular health. The ideal condition of mitochondria depends not only on their morphology but also on various micro-environmental factors, including pH, polarity, and temperature. Changes in these factors or malfunctions of mitochondrial species, such as Reactive Oxygen Species (ROS), active nitrogen species, metal cations, anions, and protons, can lead to several diseases in humans, including heart failure, kidney disorders, diabetes, Alzheimer's disease, and Parkinson's disease. Therefore, monitoring Reactive Small Molecules (RSMs), maintaining micro-environmental factors, and estimating ROS levels in mitochondria are essential for understanding physiological behaviour and the pathogenesis of related diseases. Irregularities in mitochondrial function are closely linked to a range of clinical conditions, highlighting the importance of targeting mitochondria for therapeutic benefits. Over the last decade, numerous studies have focused on the development of small organic conjugated systems for mitochondrial imaging, utilizing optical signal transduction pathways. In this review, the design and synthetic strategies for small organic fluorophores conjugated with a pyridinium acceptor, their applications in mitochondrial imaging, and the detection of RSMs in mitochondria have been discussed. Studies have revealed that small-molecule fluorescent probes are being widely used for the detection and imaging of RSMs located in mitochondria. Moreover, this review covers the mechanistic insights, photophysical properties, biological characteristics of fluorophores, and therapeutic strategies targeting the mitochondria of human cells.</p>","PeriodicalId":10845,"journal":{"name":"Current pharmaceutical design","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144945784","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Brusatol Regulates Ferroptosis of Ovarian Cancer Through the Nrf2/HO-1/NQO1 and AKT/mTOR Double Signaling Pathways.","authors":"Hongli Liu, Luyao Wang, Mengling Hu, Jiale Hua, Xiaofu Lian, Chaoqun Lian, Jing Zhang","doi":"10.2174/0113816128383328250808123933","DOIUrl":"https://doi.org/10.2174/0113816128383328250808123933","url":null,"abstract":"<p><strong>Introduction: </strong>Ovarian cancer (OC) is a common malignant tumor of the female reproductive system and is usually found at an advanced stage. However, the treatment of OC with conventional the efficacy of surgery and chemotherapy is limited. Brusatol (BRU) is a unique nuclear factor erythroid 2-related factor 2 (Nrf2) pathway inhibitor with significant anti-cancer effects. At the same time, the Nrf2 system also plays a vital role in ferroptosis, which can be used as a new way to treat tumors. This study investigated the mechanism of action of BRU as a novel ferroptosis inducer to inhibit OC cells.</p><p><strong>Methods: </strong>Using bioinformatics to screen for key targets and pathways that act on OC in BRU, and then the effects of BRU on OC cells were examined by cell viability assay, clone formation assay, wound healing assay, and apoptosis assay. The intracellular levels of ROS (Reactive Oxygen Species), Fe2+, glutathione (GSH), and malondialdehyde (MDA) were also quantified. Western blotting analysis was then performed to verify ferroptosis marker proteins and pathways. In addition, the combination of Ferrostatin-1 (Fer-1) and BRU was further tested for ferroptosis-related markers.</p><p><strong>Results: </strong>By obtaining BRU and OC targets, 171 potential BRU-OC action targets were screened to the core target NQO1. KEGG enrichment analysis showed that the anticancer effects of IBC were mediated through multiple pathways, including the PI3K-AKT and Ras signaling pathways. In vitro results showed that IBC inhibited the proliferation, invasion, and migration of OC cells and induced ferroptosis in OC cells.</p><p><strong>Discussion: </strong>We demonstrated that BRU increased intracellular ROS, Fe2+, and MDA levels. It also significantly reduced intracellular GSH level and the expression of two marker proteins for ferroptosis, GPX4 and SLC7A11. Meanwhile, BRU could inhibit the Nrf2/HO-1/NQO1 and AKT/mTOR dual signaling pathways in OC cells. Furthermore, the combination of Ferrostatin-1 (Fer-1) and BRU reversed BRU-induced ferroptosis in OC cells.</p><p><strong>Conclusion: </strong>In this study, we demonstrated for the first time through bioinformatics, molecular docking technology, and experimental validation that BRU acts as a novel inducer of ferroptosis in ovarian cancer cells by targeting the Nrf2/HO-1/NQO1 and AKT/mTOR dual signaling pathways, and may have great potential in the treatment of ovarian cancer cells.</p>","PeriodicalId":10845,"journal":{"name":"Current pharmaceutical design","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145014138","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nanotechnology-Driven Therapeutic Potential of Raloxifene in Osteoporosis and Cancer: A Recent Review.","authors":"Mohit Kumar, Anjali Pant, Syed Mahmood","doi":"10.2174/0113816128374654250801180801","DOIUrl":"https://doi.org/10.2174/0113816128374654250801180801","url":null,"abstract":"<p><strong>Introduction: </strong>Osteoporosis (OP) is a prevalent condition in postmenopausal women, marked by reduced bone density and an increased risk of fractures. Raloxifene (RLX), a selective estrogen receptor modulator (SERM), is the only drug approved for the management of OP in this patient population. RLX works by mimicking estrogen's effects on bone, reducing bone resorption and thereby increasing bone mineral density. However, despite its benefits, conventional oral RLX formulations have significant limitations. Its low bioavailability and poor aqueous solubility are compounded by extensive first-pass metabolism, which significantly reduces the drug's efficacy. Recent research has focused on nanocarriers for RLX to overcome these challenges, with lipid-based nanocarriers emerging as a promising approach to improve solubility, enhance absorption, and bypass first-pass metabolism via lymphatic uptake.</p><p><strong>Method: </strong>The authors gathered information about RLX from articles published up to 2025 and listed in Pub- Med, Web of Science, Elsevier, Google Scholar, and similar databases. The keywords used in our search included \"Osteoporosis\" \"Raloxifene\" \"nanocarriers\" etc. Results: The review of existing literature reveals substantial progress in developing innovative drug delivery systems for RLX, aimed at overcoming the limitations of conventional oral dosage forms in the treatment of OP and cancer. Several studies underscore the potential of novel formulations, including lipid-based nanocarriers, to improve raloxifene's pharmacokinetic profile, particularly through enhanced solubility, dissolution rate, and bioavailability.</p><p><strong>Conclusion: </strong>The nanocarriers mediated raloxifene delivery represent promising strategies to enhance its bioavailability and therapeutic efficacy in osteoporosis treatment. By improving solubility and bypassing first-pass metabolism, these novel systems can potentially reduce dose-related side effects, offering safer and more effective long-term options for postmenopausal women with osteoporosis. This approach supports the continued exploration of both oral and non-oral delivery methods to overcome the limitations of conventional raloxifene formulations.</p>","PeriodicalId":10845,"journal":{"name":"Current pharmaceutical design","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-08-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144946077","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Inclusion Complexes of α and β-cyclodextrin with Canagliflozin Hemihydrate: Design and Characterization.","authors":"Priyanka Gauniya, Chitra, Mukesh Pandey, Radheshyam, Ajay Semalty, Mukul Gupta, Archna Sagdeo, Mona Semalty","doi":"10.2174/0113816128384484250729091344","DOIUrl":"https://doi.org/10.2174/0113816128384484250729091344","url":null,"abstract":"<p><strong>Introduction: </strong>Canagliflozin hemihydrate (CANA), an antidiabetic drug that functions as a sodiumglucose co-transporter 2 (SGLT2) inhibitor, is classified under the Biopharmaceutical Classification System (BCS) as a Class IV drug, characterized by low solubility and low permeability. This study aimed to enhance the solubility, dissolution, and permeability of CANA by preparing its inclusion complexes with α- cyclodextrin (α-CD) and β-cyclodextrin (β-CD), followed by characterization of their crystalline and biopharmaceutical properties.</p><p><strong>Methods: </strong>The solubility of CANA in aqueous medium and phase solubility with α and β-cyclodextrin were conducted. The inclusion complexes in different CANA: α-CD ratios (1:0.25 to 1:6 mM) and CANA: β-CD ratios (1:0.50 to 1:8 mM) were prepared using the freeze-drying method. The complexes were subjected to drug content analysis, Fourier transform infrared spectroscopy (FTIR), X-ray powder diffraction (XRPD), angle- dispersive X-ray diffraction (ADXRD), in vitro dissolution, and permeation studies.</p><p><strong>Results: </strong>Phase solubility study indicated significant improvements in aqueous solubility of CANA with α-CD and β-CD. The solubility of CANA increased significantly (more than 100-fold in BCD8 with 0.577 mg/mL) upon complexation. BCD8 (1:7) with 97.366% and ACD6 (1:4) with 94.6% showed the highest % drug content. FTIR confirmed interactions between CANA and CDs due to the disappearance or shifting of some characteristic peaks (e.g., 3390.68 to 3268.91 cm-1 and 1078.07 to 1024.06 cm-1 in ACD6, while 3265.05 to 3268.91 cm⁻¹ and 1025.99 to 1024.06 cm⁻¹ in ACD7).</p><p><strong>Discussion: </strong>XRPD and ADXRD showed the crystalline nature of CANA and CDs, while the complexes exhibited amorphization with diffused peaks. The lowest crystallite size was observed in ACD6 (449.688) and the highest in ACD3 (966.936 Å). D-spacing was found to be smallest in ACD8 (0.722 Å) and BCD6 (4.080 Å), and the highest in ACD1 (7.276 Å), BCD7, and BCD8 (7.063 Å). The drug release ranged from 64.265% (ACD3) to 94.306% (BCD7) and increased with lower crystallinity. ACD8 (87.33%) and BCD7 (93.41%) exhibited the highest % of drug permeability.</p><p><strong>Conclusion: </strong>Inclusion complexation with α-CD and β-CD significantly improved the solubility and dissolution of CANA in aqueous medium. These findings suggest that cyclodextrin-based inclusion complexes offer a promising approach to enhancing the biopharmaceutical performance of poorly soluble drugs, such as CANA.</p>","PeriodicalId":10845,"journal":{"name":"Current pharmaceutical design","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144945988","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring the Neurobiological Mechanisms of Cancer Growth.","authors":"Md Sadique Hussain, Mudasir Maqbool, Mohit Agrawal, Amita Joshi Rana, Ayesha Sultana, Nasreen Sulthana, Ajay Singh Bisht, Gyas Khan","doi":"10.2174/0113816128402718250806151308","DOIUrl":"https://doi.org/10.2174/0113816128402718250806151308","url":null,"abstract":"<p><p>Emerging evidence reveals that interactions between the nervous system and tumor biology significantly influence cancer progression, metastasis, and therapeutic outcomes. This review elucidates the neurobiological mechanisms that underpin tumor development, highlighting the dynamic role of neural components within the tumor microenvironment (TME). Neural signals and structural adaptations in the TME stimulate tumorigenesis and enable cancer cell plasticity, mimicking neurodevelopmental processes. Astrocytic glial cells release neurotrophic factors that support metastatic colonization and enhance tumor cell survival. Notably, cancer cells can establish pseudo-tripartite synapses with neurons, promoting both proliferation and invasion. We explore the cancer-neural network interplay, emphasizing how axonal remodeling, circuit reorganization, and synaptic dysfunction not only drive tumor growth but also contribute to associated symptoms like seizures and chronic pain. Molecularly, mutations such as in PIK3CA and abnormalities in neurotransmitter signaling reveal how neuro-tumors communicate and adapt. Furthermore, metabolic stress responses from tumor cells can activate nociceptive neurons, sustaining malignant progression. Understanding these neurobiological interactions opens avenues for novel therapeutic strategies. Precision neuro-oncology may benefit from targeting neurotrophic signaling, synaptic pathways, and neuronal differentiation programs. Advances in biomarker research from neuro-tumors also contribute to improved diagnostic and prognostic tools. By integrating neuroscience insights into oncological frameworks, we propose a paradigm shift toward therapies that intercept the neural circuitry sustaining malignancies. This neuro-oncological approach holds promise in addressing aggressive cancer phenotypes and improving patient outcomes.</p>","PeriodicalId":10845,"journal":{"name":"Current pharmaceutical design","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144854830","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Neuro-protective Potential of Honey: A Narrative Review.","authors":"Sumel Ashique, Anas Islam, Prashant Kumar, Samy Selim, Soad K Al Jaouni, Ananya Chakraborty, Ivan Kahwa, Rajat Goyal, Shivani Chopra, Hitesh Chopra","doi":"10.2174/0113816128383966250726122514","DOIUrl":"https://doi.org/10.2174/0113816128383966250726122514","url":null,"abstract":"<p><p>Apitherapy, the therapeutic use of bee products, has attracted attention for its potential in treating various ailments. Honey is unique among bee products because it has a high concentration of medicinal chemicals. In recent years, there has been growing concern about exploring the neuroprotective features of honey. Our article aimed to consolidate existing research on the neuroprotective potential of honey, shedding more focus on its mechanisms of action and therapeutic properties. The literature suggests that honey exhibits neuroprotective properties by attenuating oxidative stress, alleviating neuroinflammation, and enhancing neuronal survival and regeneration. Especially, honey's potential to mitigate neurodegenerative disorders and enhance cognitive function and memory. These reports position honey as a promising candidate for neuroprotection, offering a natural and accessible therapeutic option to combat neurological disorders. Its multifaceted mechanism of action makes it a valuable asset in neurotherapy. However, more research is warranted to clarify the specific compounds responsible for their neuroprotective effects and to optimize their therapeutic application. Unlocking the full potential of honey in neuroprotection could open the door to novel therapeutic approaches for the management of neurological conditions.</p>","PeriodicalId":10845,"journal":{"name":"Current pharmaceutical design","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144854832","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}